Markets

Top Stock Reports for Coca-Cola, Eli Lilly & Occidental Petroleum

Friday, March 9, 2018

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola (KO), Eli Lilly (LLY) and Occidental Petroleum (OXY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Coca-Cola 's shares have underperformed the Zacks Soft Drinks Beverages industry in the last one year, (+5.1% vs. +6.6%). Coca-Cola reported better-than-expected fourth-quarter 2017 results, ending the year on an impressive note.

Despite reporting flat soda volumes, the cola giant gained from its growing beverage portfolio and re-structuring efforts. Organic revenues grew 6% with growth across the board, driven by price/mix growth of 4% and concentrate sales growth of 1%. Again, lower SG&A expenses (down 21%), higher gross margin (up 480 basis points or bps) and higher operating margin (up 540 bps) helped it come up with better numbers.

However, total sales decreased 20%, marking the 11th consecutive quarterly decline in revenues. Although top line needs to show sustained improvement, the Zacks analyst is encouraged by the company's strategic efforts in making its portfolio much like that of a total beverage company with improved marketing and innovation, focus on driving revenues by improved price/mix, digital focus, and productivity initiatives toward driving margins.

(You can read the full research report on Coca-Cola here >>> ).

Eli Lilly 's shares have underperformed the Zacks Large-Cap Pharmaceuticals industry in the last one year (down -6.5% vs. +8.9%). Lilly's new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018.

Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. The decision to sell or spin-off the Animal Health segment, which has underperformed in 2017, is a prudent decision, according to the Zacks analyst. Also, competitive pressure on Lilly's drugs is expected to rise this year.

Meanwhile, challenges remain for the company in the form of loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018.

(You can read the full research report on Eli Lily here >>> ).

Strong Buy-ranked Occidental Petroleum 's shares have underperformed the Zacks Domestic Integrated Oil industry over the last six months, gaining +4.2% vs. +11.5%. However, Occidental Petroleum's fourth-quarter earnings per share and total revenues both came in above expectations.

As oil prices continue to improve, Occidental Petroleum gains from more oil production in the Permian Resources and concentrating on high-margin production region. The ongoing capital investment fundamental strength of the company will help it overcome the adverse impact from natural disasters.

The company generates stable cash flow and its Chemical plant will further improve its cash flow. Occidental Petroleum, like other oil and natural gas companies, faces the risks of cost overruns and development interruptions due to delays in drilling and other approvals, property or border disputes and equipment failures.

(You can read the full research report on Occidental Petroleum here >>> ).

Other noteworthy reports we are featuring today include Williams (WMB), Ross Stores (ROST) and Wynn Resorts (WYNN).

Don't Even Think About Buying Bitcoin Until You Read This

The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.

Zacks' has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 4 crypto-related stocks now >>

Mark Vickery

Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Featured Reports

New Upgrades

New Downgrades

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More